Medicare Part D Spending on Single-Enantiomer Drugs Versus Their Racemic Precursors-Reference-Cited by-同舟云学术

Medicare Part D Spending on Single-Enantiomer Drugs Versus Their Racemic Precursors

Published:2019-08-13 Issue:7 Volume:171 Page:521
ISSN:0003-4819
Container-title:Annals of Internal Medicine
language:en
Short-container-title:Ann Intern Med

Author:

Egilman Alexander C.¹,Zhang Audrey D.²,Wallach Joshua D.³,Ross Joseph S.⁴

Affiliation:

1. Center for Outcomes Research and Evaluation, Yale-New Haven Health System, and the Collaboration for Research Integrity and Transparency, Yale Law School, New Haven, Connecticut (A.C.E.)

2. New York University School of Medicine, New York, New York (A.D.Z.)

3. Yale School of Public Health and the Collaboration for Research Integrity and Transparency, Yale Law School, New Haven, Connecticut (J.D.W.)

4. Yale School of Medicine, Yale School of Public Health, and the Center for Outcomes Research and Evaluation, Yale-New Haven Health System, New Haven, Connecticut (J.S.R.)

Funder

Laura and John Arnold Foundation

Publisher

American College of Physicians

Subject

General Medicine,Internal Medicine

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Out-of-pocket costs of oral anticancer drugs for Medicare beneficiaries vary by strength and formulation;Journal of Geriatric Oncology;2023-01

2. Chiral Resolution, Absolute Configuration Assignment, and Genotoxicity Evaluation of Racemic 3,4-Dihydroquinazoline as a Novel Anticancer Agent;Journal of Chemistry;2021-10-25

3. Estimating Rebates and Other Discounts Received by Medicare Part D;JAMA Health Forum;2021-06-04

4. Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors;JAMA Network Open;2021-05-06

5. FDA Approval and Regulation of Pharmaceuticals, 1983-2018;JAMA;2020-01-14